Pages,Columns,Lines where

Under the Paperwork Reduction Act of 1995, no persons are required to

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		10560445			
Filing Date		2005-12-13			
First Named Inventor	Miki Sudo				
Art Unit		1773			
Examiner Name					
Attorney Docket Number		09792909-6562			

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	1 Issue Date		Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1										
If you wis	h to a	dd additional U.S. Pater	t citatio	n inform	ation pl	ease click the	Add button.		Add		
			U.S.P	ATENT	APPLI	CATION PUBL	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Publication Code ¹ Date		tion	Name of Pate of cited Docu	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear				
	1										
If you wisl	h to a	dd additional U.S. Publi	shed Ap	plication	citatio	n information p	lease click the Ad	d butto	n. Add		
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document		where Rel	or Relevant	T
	1	05-116242	JP			1993-05-14	Toyo ink Mfg Co Lt	d			×
	2	10-100356	JP			1998-04-21	Toray Ind Inc				×
	3	11-189708	JP			1999-07-13	Tsutsunaka Plast Ir Lid	nd Co			×

U.S. PATENTS

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10560445			
Filing Date		2005-12-13			
First Named Inventor	Miki S	Rudo			
Art Unit		1773			
Examiner Name					
Attorney Docket Number		09792909-6562			

	4	11-254578	JP		1999-09-21	Toray Ind Inc		×
	5	2000-137782	JP		2000-05-16	Toppan Printing Co Ltd		×
	6	2000-242760	JP		2000-09-08	Denso Corp		×
	7	2002-331633	JP		2002-11-19	Toray Ind Inc		×
	8	2003-191422	JP		2003-07-08	Toppan Printing Co Ltd		×
If you wish to add additional Foreign Patent Document citation information please click the Add button Add								

NON-PATENT LITERATURE DOCUMENTS Remove)

Examine Cite include name of the author (in CAPTAL LETTERS), title of the article (when appropriate), tits of the item (notice management, purel serial symposium, catalog, etc), date, pagest(s), volume-tessae number(s).

1 Japanese Office Action issued on December 20, 2006

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant,

16ex Kinz Codes of USPTO Detect Documents at sweet ISSTID CODY or MRCP 98164. * Enter date that issued the document, by the bookster code (IRPO Standard 51.3) ** Explaines patient documents, the includes or the year of the register terms procedule to write the plant document. *
*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard 51.16 if possible. * Applicant is to place a check mark here if Emphilia braiquage translations is attacked.

Examiner Signature

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number		10560445		
Filing Date			2005-12-13		
	First Named Inventor Miki S Art Unit Examiner Name		Sudo		
			1773		
Attorney Docket Number		er	09792909-6562		

CERTIFICATION STATEMENT

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e/11).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office is a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1/56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1/97(c).

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Places see 37 CFR 1 97 and 1 98 to make the appropriate selection(s):

¬ N--

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	Date (YYYY-MM-DD)	
Name/Drint	Designation Number	ï

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenary Cfing. U.S. Operatment of Commence, P. 0. Box 1450, Alexandria, V.S. 2313-1450. D. ONT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral purpuses for which the information is used by the U.S. Patient and Trademan Colline is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested region of the patient of the patient application of the patient application of the patient activities, which may result in farministion of proceedings or 4 anahoroment of the application of the patients of the pa

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.